Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure

  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Martínez, Jaume Barallat
  • Pastor Ferrer, Maria Cruz
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Zamora, Elisabet|||0000-0001-5317-7481
  • Sanchis, Juan|||0000-0003-0797-8709
  • Rosés, Josep Lupón
Despite advances in pharmacologic therapy and devices, patients with heart failure (HF) continue to have significant rehospitalization rates and risk prediction remains challenging. We sought to explore the value of a multi-biomarker panel [including NT-proBNP, high-sensitivity cardiac troponin T (hs-TnT), and ST2] on top of clinical assessment for long-term prediction of recurrent hospitalizations in HF. NT-proBNP, hs-TnT, and ST2 (suppression of tumorigenicity-2) levels were measured in 891 consecutive ambulatory HF patients. The independent association between the multi-biomarker panel and recurrent hospitalizations was assessed through a multivariable negative binomial regression and expressed as incidence rates ratios. McFadden pseudo- R 2 and goodness-of-fit measures were also used. The total number of unplanned hospitalizations [all-cause, cardiovascular (CV)-, and HF-related] were selected as the primary endpoints. At a mean follow-up of 4.2 ± 2.1 years, 1623 all-cause hospitalizations in 498 patients (55.9%), 710 CV-related hospitalizations in 331 patients (37.2%), and 444 HF-related hospitalizations in 214 patients (24.1%) were registered. The crude incidence of all-cause, CV-, and HF-related recurrent hospitalizations was significantly higher for patients with the multi-biomarker panel above the cut-point (hs-TnT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Relationship among LRP1 expression, Pyk2 phosphorylation and MMP-9 activation in left ventricular remodelling after myocardial infarction

  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Soler-Botija, Carol
  • Nasarre, Laura
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Left ventricular (LV) remodelling after myocardial infarction (MI) is a crucial determinant of the clinical course of heart failure. Matrix metalloproteinase (MMP) activation is strongly associated with LV remodelling after MI. Elucidation of plasma membrane receptors related to the activation of specific MMPs is fundamental for treating adverse cardiac remodelling after MI. The aim of current investigation was to explore the potential association between the low-density lipoprotein receptor-related protein 1 (LRP1) and MMP-9 and MMP-2 spatiotemporal expression after MI. Real-time PCR and Western blot analyses showed that LRP1 mRNA and protein expression levels, respectively, were significantly increased in peri-infarct and infarct zones at 10 and 21 days after MI. Confocal microscopy demonstrated high colocalization between LRP1 and the fibroblast marker vimentin, indicating that LRP1 is mostly expressed by cardiac fibroblasts in peri-infarct and infarct areas. LRP1 also colocalized with proline-rich tyrosine kinase 2 (pPyk2) and MMP-9 in cardiac fibroblasts in ischaemic areas at 10 and 21 days after MI. Cell culture experiments revealed that hypoxia increases LRP1, pPyk2 protein levels and MMP-9 activity in fibroblasts, without significant changes in MMP-2 activity. MMP-9 activation by hypoxia requires LRP1 and Pyk2 phosphorylation in fibroblasts. Collectively, our in vivo and in vitro data support a major role of cardiac fibroblast LRP1 levels on MMP-9 up-regulation associated with ventricular remodelling after MI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction

  • Bobi, Joaquim|||0000-0002-9026-5226
  • Solanes, Núria
  • Fernández-Jiménez, Rodrigo
  • Galán-Arriola, Carlos
  • Dantas, A. P.|||0000-0001-8514-4094
  • Fernández-Friera, Leticia
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rigol-Monzó, Elisabet
  • Agüero, Jaume|||0000-0001-7416-871X
  • Ramírez, José
  • Roqué, Mercè
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sánchez González, Javier|||0000-0003-1427-3870
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Sabaté, Manel
  • Rudilla, F..
  • Ibañez, Borja|||0000-0002-5036-254X
  • Rigol, Montserrat
Autologous adipose tissue-derived mesenchymal stem cells (s) therapy is a promising strategy to improve post-myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the mechanisms involved in allogeneic s administration on myocardial performance. Thirty-eight pigs underwent 50 minutes of coronary occlusion; the study was completed in 33 pigs. After reperfusion, allogeneic s or culture medium (vehicle) were intracoronarily administered. Follow-ups were performed at short (2 days after acute myocardial infarction vehicle-treated, n=10; s-treated, n=9) or long term (60 days after acute myocardial infarction vehicle-treated, n=7; s-treated, n=7). At short term, infarcted myocardium analysis showed reduced apoptosis in the s-treated animals (48.6±6% versus 55.9±5.7% in vehicle; P =0.017); enhancement of the reparative process with up-regulated vascular endothelial growth factor, granulocyte macrophage colony-stimulating factor, and stromal-derived factor-1α gene expression; and increased M2 macrophages (67.2±10% versus 54.7±10.2% in vehicle; P =0.016). In long-term groups, increase in myocardial perfusion at the anterior infarct border was observed both on day-7 and day-60 cardiac magnetic resonance studies in s-treated animals, compared to vehicle (87.9±28.7 versus 57.4±17.7 mL/min per gram at 7 days; P =0.034 and 99±22.6 versus 43.3±14.7 22.6 mL/min per gram at 60 days; P =0.0001, respectively). At day 60, higher vascular density was detected at the border zone in the s-treated animals (118±18 versus 92.4±24.3 vessels/mm 2 in vehicle; P =0.045). Cardiac magnetic resonance-measured left ventricular ejection fraction of left ventricular volumes was not different between groups at any time point. In this porcine acute myocardial infarction model, allogeneic s-based therapy was associated with increased cardioprotective and reparative mechanisms and with better cardiac magnetic resonance-measured perfusion. No effect on left ventricular volumes or ejection fraction was observed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unravelling the effects of mechanical physiological conditioning on cardiac adipose tissue-derived progenitor cells in vitro and in silico

  • Llucià-Valldeperas, Aida
  • Bragos, Ramon|||0000-0002-1373-1588
  • Soler Botija, Carolina
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Perea Gil, Isaac
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Mechanical conditioning is incompletely characterized for stimulating therapeutic cells within the physiological range. We sought to unravel the mechanism of action underlying mechanical conditioning of adipose tissue-derived progenitor cells (ATDPCs), both in vitro and in silico. Cardiac ATDPCs, grown on 3 different patterned surfaces, were mechanically stretched for 7 days at 1 Hz. A custom-designed, magnet-based, mechanical stimulator device was developed to apply ~10% mechanical stretching to monolayer cell cultures. Gene and protein analyses were performed for each cell type and condition. Cell supernatants were also collected to analyze secreted proteins and construct an artificial neural network. Gene and protein modulations were different for each surface pattern. After mechanostimulation, cardiac ATDPCs increased the expression of structural genes and there was a rising trend on cardiac transcription factors. Finally, secretome analyses revealed upregulation of proteins associated with both myocardial infarction and cardiac regeneration, such as regulators of the immune response, angiogenesis or cell adhesion. To conclude, mechanical conditioning of cardiac ATDPCs enhanced the expression of early and late cardiac genes in vitro. Additionally, in silico analyses of secreted proteins showed that mechanical stimulation of cardiac ATDPCs was highly associated with myocardial infarction and repair.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function

  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rudilla, F..
  • Llucià-Valldeperas, Aida
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Díaz-Güemes, Idoia
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Myocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a cell-enriched myocardial graft, composed of a decellularized myocardial matrix refilled with adipose tissue-derived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-ATDPC improved cardiac function, reduced infarct size, attenuated fibrosis progression, and promoted neovascularization of the ischemic myocardium. The beneficial effects exerted by the EMG-ATDPC and the absence of identified adverse side effects should facilitate its clinical translation as a novel MI therapy in humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing

  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bragos, Ramon|||0000-0002-1373-1588
  • Soler Botija, Carolina
  • Díaz-Güemes, Idoia
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Llucià-Valldeperas, Aida
  • Bogónez-Franco, Paco|||0000-0002-5364-231X
  • Perea Gil, Isaac
  • Rudilla, F..
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac tissue engineering, which combines cells and biomaterials, is promising for limiting the sequelae of myocardial infarction (MI). We assessed myocardial function and scar evolution after implanting an engineered bioactive impedance graft (EBIG) in a swine MI model. The EBIG comprises a scaffold of decellularized human pericardium, green fluorescent protein-labeled porcine adipose tissue-derived progenitor cells (pATPCs), and a customized-design electrical impedance spectroscopy (EIS) monitoring system. Cardiac function was evaluated noninvasively by using magnetic resonance imaging (MRI). Scar healing was evaluated by using the EIS system within the implanted graft. Additionally, infarct size, fibrosis, and inflammation were explored by histopathology. Upon sacrifice 1 month after the intervention, MRI detected a significant improvement in left ventricular ejection fraction (7.5%64.9% vs. 1.4%63.7%; p = .038) and stroke volume (11.565.9 ml vs. 364.5 ml; p = .019) in EBIG-treated animals. Noninvasive EIS data analysis showed differences in both impedance magnitude ratio (20.02 6 0.04 per day vs. 20.48 6 0.07 per day; p = .002) and phase angle slope (20.18°60.24° per day vs.23.52°60.84° per day; p = .004) in EBIG compared with control animals. Moreover, in EBIG-treated animals, the infarct size was 48% smaller (3.4%60.6% vs. 6.5%61%; p = .015), less inflammation was found by means of CD25+ lymphocytes (0.65 6 0.12 vs. 1.26 6 0.2; p = .006), and a lower collagen I/III ratio was detected (0.4960.06 vs. 1.6660.5; p = .019). An EBIG composed of acellular pericardium refilled with pATPCs significantly reduced infarct size and improved cardiac function in a preclinical model of MI. Noninvasive EIS monitoring was useful for tracking differential scar healing in EBIG-treated animals, which was confirmed by less inflammation and altered collagen deposit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mesenchymal stem cells induce expression of cD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively. This shifts the pro-inflammatory milieu induced by extracellular ATP to the anti- inflammatory regulation by Ado. Mesenchymal stem cells (MSCs) have potent immunomodulatory capabilities, including monocyte modulation toward an anti-inflammatory phenotype aiding tissue repair. In vitro, we observed that human cardiac adipose tissue-derived MSCs (cATMSCs) and umbilical cord MSCs similarly polarize monocytes toward a regulatory M2 phenotype, which maintained the expression of CD39 and induced expression of CD73 in a cell contact dependent fashion, correlating with increased functional activity. In addition, the local treatment with porcine cATMSCs using an engineered bioactive graft promoted the in vivo CD73 expression on host monocytes in a swine model of myocardial infarction. Our results suggest the upregulation of ectonucleotidases on MSC-conditioned monocytes as an effective mechanism to amplify the long-lasting immunomodulatory and healing effects of MSCs delivery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  • Pacho Pacho, Cristina
  • Domingo, Mar|||0000-0002-2935-1272
  • Núñez Aragón, Raquel
  • Lupón, Josep|||0000-0002-5601-9611
  • Núñez, Julio|||0000-0003-1672-7119
  • Barallat, Jaume|||0000-0003-3493-5958
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Santesmases Ejarque, Javier|||0000-0002-1226-1617
  • Cediel, Germán|||0000-0001-9667-7507
  • Roura, Santiago|||0000-0003-4063-9661
  • Pastor, M. Cruz
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mortality alone at one year was also a major endpoint. HF-related rehospitalizations alone were secondary end-points. From February 2014 to November 2016, 522 consecutive patients attending the STOP-HF Clinic were included (57.1% women, age 82 ± 8.7 years, mean Barthel index 70 ± 25, mean Charlson comorbidity index 5.6 ± 2.2). The composite endpoint occurred in 8.6% patients at 30 days and in 38.5% at 1 year. In multivariable analysis, ST2 [hazard ratio (HR) 1.53; 95% CI 1.19-1.97; p = 0.001] was the only predictive biomarker at 30 days; at 1 year, both ST2 (HR 1.34; 95% CI 1.15-1.56; p < 0.001) and NT-proBNP (HR 1.19; 95% CI 1.02-1.40; p = 0.03) remained significant. The addition of ST2 and NT-proBNP into a clinical predictive model increased the AUC from 0.70 to 0.75 at 30 days (p = 0.02) and from 0.71 to 0.74 at 1 year (p < 0.05). For all-cause death at 1 year, ST2 (HR 1.50; 95% CI 1.26-1.80; p < 0.001), and CA125 (HR 1.41; 95% CI 1.21-1.63; p < 0.001) remained independent predictors in multivariable analysis. The addition of ST2 and CA125 into a clinical predictive model increased the AUC from 0.74 to 0.78 (p = 0.03). For HF-related hospitalizations, ST2 was the only predictive biomarker in multivariable analyses, both at 30 days and at 1 year. In a comorbid frail elderly population with HFpEF, ST2 outperformed NT-proBNP for predicting the risk of all-cause mortality or HF-related rehospitalization. ST2, a surrogate marker of inflammation and fibrosis, may be a better predictive marker in high-risk HFpEF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts

  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Fernandez-Figueras, M. Teresa
  • Martí, Mercè|||0000-0002-1846-0043
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Roura, Santiago|||0000-0003-4063-9661
  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Llucià-Valldeperas, Aida
  • Raya, Ángel|||0000-0003-2189-9775
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Engineered bioimplants for cardiac repair require functional vascularization and innervation for proper integration with the surrounding myocardium. The aim of this work was to study nerve sprouting and neovascularization in an acellular pericardial-derived scaffold used as a myocardial bioimplant. To this end, 17 swine were submitted to a myocardial infarction followed by implantation of a decellularized human pericardial-derived scaffold. After 30 days, animals were sacrificed and hearts were analyzed with hematoxylin/eosin and Masson's and Gallego's modified trichrome staining. Immunohistochemistry was carried out to detect nerve fibers within the cardiac bioimplant by using βIII tubulin and S100 labeling. Isolectin B4, smooth muscle actin, CD31, von Willebrand factor, cardiac troponin I, and elastin antibodies were used to study scaffold vascularization. Transmission electron microscopy was performed to confirm the presence of vascular and nervous ultrastructures. Left ventricular ejection fraction (LVEF), cardiac output (CO), stroke volume, end-diastolic volume, end-systolic volume, end-diastolic wall mass, and infarct size were assessed by using magnetic resonance imaging (MRI). Newly formed nerve fibers composed of several amyelinated axons as the afferent nerve endings of the heart were identified by immunohistochemistry. Additionally, neovessel formation occurred spontaneously as small and large isolectin B4-positive blood vessels within the scaffold. In summary, this study demonstrates for the first time the neoformation of vessels and nerves in cell-free cardiac scaffolds applied over infarcted tissue. Moreover, MRI analysis showed a significant improvement in LVEF (P = 0.03) and CO (P = 0.01) and a 43 % decrease in infarct size (P = 0.007).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo experience with natural scaffolds for myocardial infarction, the times they are a-changin'

  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Treating a myocardial infarction (MI), the most frequent cause of death worldwide, remains one of the most exciting medical challenges in the 21st century. Cardiac tissue engineering, a novel emerging treatment, involves the use of therapeutic cells supported by a scaffold for regenerating the infarcted area. It is essential to select the appropriate scaffold material; the ideal one should provide a suitable cellular microenvironment, mimic the native myocardium, and allow mechanical and electrical coupling with host tissues. Among available scaffold materials, natural scaffolds are preferable for achieving these purposes because they possess myocardial extracellular matrix properties and structures. Here, we review several natural scaffolds for applications in MI management, with a focus on pre-clinical studies and clinical trials performed to date. We also evaluate scaffolds combined with different cell types and proteins for their ability to promote improved heart function, contractility and neovascularization, and attenuate adverse ventricular remodeling. Although further refinement is necessary in the coming years, promising results indicate that natural scaffolds may be a valuable translational therapeutic option with clinical impact in MI repair.